The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS

PharmacoEconomics

Volumn 18, Issue 4, 2000, Pages 393-404

  Anis, A H ^a   Guh, D ^b   Hogg, R S ^a   Wang, X H ^b   Yip, B ^a   Craib, K J P ^b   O'Shaughnessy, M V ^a   Schechter, M T ^a   Montaner, J S G ^a  

^a ST PAUL S HOSPITAL   (Canada)

^b Canadian HIV Trials Network   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COLOMBIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE FINANCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033779153     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018040-00007     Document Type: Article

References (21)

1. Current controversies in the treatment of HIV infection and AIDS
2. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection
3. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection
4. Combination antiretroviral therapy in HIV infection
5. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients
6. The economic impact of AIDS in the United States
7. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991
8. The cost-effectiveness of preventing AIDS-related opportunistic infections
9. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
10. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: Lessons from the implementation of viral load driven antiretroviral therapy
11. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the international AIDS society - USA panel
12. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
13. Acquired immune deficiency syndrome (AIDS) interim proposal for a WHO staging system for HIV infection and disease
14. Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men
15. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults [no RR-17]
16. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy
17. Cost-effectiveness leagues tables: More harm than good?
18. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
19. Pharmaceutical prices with insurance coverage and formularies